Pemetrexed, Cisplatin With Soft Tissue Sarcoma

Soft tissue sarcoma (STS) is rare malignancy of mesodermal origin, representing less than 1% of all malignant neoplasms. They are a group of diseases encompassing diverse histological subtypes with very different biomorphologies, prognoses, and responses to treatments. At advanced stages of STS, anticancer treatments are less effective and the prognosis is poor with a median survival of 8 to 18 months. Doxorubicin and ifosfamide given each alone or in their combination have represented the mainstream of anticancer treatments in metastatic STS. However, salvage treatments for patients with prog

Trial Details

NCT ID
NCT04605770
Phase
PHASE2
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • pemetrexed+cisplatin
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • histologically confirmed, advanced/metastatic STS
  • Is ≥ 19 years of age
  • Eastern Cooperative Oncology Group performance status of 0 or 1
  • measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →